Daily Stock Analysis, WVE, WAVE Life Sciences Ltd, priceseries

WAVE Life Sciences Ltd. Daily Stock Analysis
Stock Information
Open
2.35
Close
2.09
High
2.35
Low
2.08
Previous Close
2.32
Daily Price Gain
-0.23
YTD High
3.40
YTD High Date
Jan 4, 2022
YTD Low
2.03
YTD Low Date
Jan 24, 2022
YTD Price Change
-1.16
YTD Gain
-35.69%
52 Week High
10.91
52 Week High Date
Mar 22, 2021
52 Week Low
2.03
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-7.83
52 Week Gain
-78.93%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 25. 2017
18.75
Sep 21. 2017
23.18
18 Trading Days
23.63%
Link
LONG
Nov 10. 2017
22.80
Dec 18. 2017
36.05
25 Trading Days
58.13%
Link
LONG
Feb 13. 2018
42.30
Mar 1. 2018
49.04
11 Trading Days
15.93%
Link
LONG
May 23. 2018
42.70
Jun 19. 2018
48.15
18 Trading Days
12.77%
Link
LONG
Feb 22. 2019
37.64
Mar 20. 2019
44.87
18 Trading Days
19.21%
Link
LONG
Oct 25. 2019
23.26
Dec 5. 2019
32.68
28 Trading Days
40.50%
Link
LONG
Aug 19. 2020
10.10
Sep 8. 2020
11.67
13 Trading Days
15.54%
Link
LONG
Sep 11. 2020
13.60
Sep 21. 2020
14.97
6 Trading Days
10.09%
Link
LONG
Nov 11. 2020
7.68
Dec 4. 2020
8.65
16 Trading Days
12.60%
Link
LONG
Jan 5. 2021
8.45
Jan 13. 2021
8.92
6 Trading Days
5.62%
Link
LONG
Feb 15. 2022
2.50
Feb 23. 2022
2.64
5 Trading Days
5.66%
Link
Company Information
Stock Symbol
WVE
Exchange
NasdaqGM
Company URL
http://www.wavelifesciences.com
Company Phone
617-206-4830
CEO
Paul B. Bolno
Headquarters
-
Business Address
8 CROSS STREET, #10-00, SINGAPORE, SINGAPORE 048424
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001631574
About

Wave Life Sciences Ltd. operates as a preclinical biopharmaceutical company. It engages in the development and provision of nucleic acid therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Cambridge, MA.

Description

Preclinical biotech developing optimized RNA therapies for rare diseases.